AST 915

Drug Profile

AST 915

Alternative Names: AST-914; AST-914 metabolite; AST-915

Latest Information Update: 02 May 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ariston Pharmaceuticals
  • Developer TG Therapeutics Inc
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Essential tremor

Most Recent Events

  • 07 Mar 2014 Discontinued - Phase-I/II for Essential tremor in USA (PO)
  • 26 Apr 2012 Clinical development is ongoing in USA
  • 03 Feb 2011 Manhattan Pharmaceuticals plans to advance AST 915 into phase II development for Essential Tremor in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top